Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...
SAN FRANCISCO--(BUSINESS WIRE)--Vor Systems, an AI-enabled transaction platform built for complex renewable energy deals, today announced it has raised $3 million in pre-seed funding led by Gigascale ...
Practical strategies for turning tutorials into active, inclusive learning spaces, from designing hands-on activities and valuing student contributions to building rapport and providing effective ...
Vor Biopharma ( (VOR)) just unveiled an update. On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with its Chief Development Officer, Dr. Qing Zuraw, following her decision ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity Vor Biopharma is estimated to be 49% undervalued based on current share price of US$7.68 Our fair value ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results